Invest in

Drug-Patent Cliffs

30.7%
13.1%
5.1%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
30.7%
13.1%
5.1%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 25.2%
20.5% Taro Pharmaceutical Industries Ltd. TARO 5.8%
19.5% Dr. Reddys Laboratories Ltd. ADS RDY 18.4%
15.1% Mylan NV MYL 42.5%
11.7% Impax Laboratories Inc. IPXL 29.1%
6.6% Sagent Pharmaceuticals Inc. SGNT 51.9%
6.2% Akorn Inc. AKRX 39.1%
5.8% Abbott Laboratories ABT 16.8%
4.2% Mallinckrodt plc MNK 47.6%
2.7% Sanofi ADR (Sponsored) SNY 16.8%
2.6% Lannett Co. Inc. LCI 66.5%
2.0% Teva Pharmaceutical Industries Ltd ADR TEVA 10.4%
1.4% Cambrex Corp. CBM 36.4%
1.2% The Medicines Company MDCO 30.2%
0.4% Endo International PLC ENDP 67.7%

Quotes delayed 15 mins. Currently May 6, 2016 2:47:18 PM. Fields are marked with -- when data is unavailable.